Singh A, Tejani C, Tejani A
New York Medical College, Hawthorne 10532, USA.
Pediatr Nephrol. 1999 Jan;13(1):26-32. doi: 10.1007/s004670050557.
Uncontrolled or refractory nephrotic syndrome (NS), seen in a variety of glomerular disorders, leads to end-stage renal disease (ESRD). This study describes the use and efficacy of cyclosporine (CSA) for the treatment of refractory NS in 83 children seen over a 10-year period. The histological diagnosis leading to the NS was focal segmental glomerulosclerosis (FSGS) in 51% (n = 42), IgM nephropathy in 20% (n = 17), membranoproliferative glomerulonephritis in 10% (n = 8), lupus nephritis in 6% (n = 5), human immunodeficiency virus (HIV) nephropathy in 5% (n = 4), minimal change disease in 7% (n = 6), and membranous nephropathy in 1% (n = 1) of patients. During CSA therapy the mean proteinuria of the study population decreased from 5.14 g/24 h (4.80 g/m2 per 24 h) to 1.23 g/24 h (0.92 g/m2 per 24 h) (P < 0.001), the mean serum albumin increased from 2.13 g/dl to 3.53 g/dl (P < 0.001), the mean serum cholesterol decreased from 364 mg/dl to 223 mg/dl (P < 0.001), and the mean serum creatinine increased from 0.77 mg/dl to 1.2 mg/dl (P < 0.01). When analyzed by histological diagnosis, similar significant trends of reduction in proteinuria were seen in all but the lupus group. There was a rise in serum creatinine following the use of CSA in patients with FSGS, lupus nephritis, and HIV nephropathy; however the elevated serum creatinine was only significant in patients with FSGS. At the end of the study period, 20 patients had reached ESRD, of which 11 had FSGS, 5 had lupus nephritis, and 4 were patients with HIV nephropathy. Fifty-four patients were in remission at the end of the study period (48 with proteinuria < 100 mg/24 h and 6 with proteinuria < 500 mg/24 h). In conclusion, among children with refractory NS, CSA induced a remission in a large proportion. However toxicity, as noted by the rise in serum creatinine, was observed in several patients. Since this toxicity may be drug induced or a natural progression of the disease, careful monitoring and close follow-up are essential.
在多种肾小球疾病中出现的未控制或难治性肾病综合征(NS)会导致终末期肾病(ESRD)。本研究描述了环孢素(CSA)在10年期间对83例儿童难治性NS的治疗应用及疗效。导致NS的组织学诊断为:局灶节段性肾小球硬化(FSGS)占51%(n = 42),IgM肾病占20%(n = 17),膜增生性肾小球肾炎占10%(n = 8),狼疮性肾炎占6%(n = 5),人类免疫缺陷病毒(HIV)肾病占5%(n = 4),微小病变病占7%(n = 6),膜性肾病占1%(n = 1)。在CSA治疗期间,研究人群的平均蛋白尿从5.14 g/24 h(4.80 g/m²每24 h)降至1.23 g/24 h(0.92 g/m²每24 h)(P < 0.001),平均血清白蛋白从2.13 g/dl升至3.53 g/dl(P < 0.001),平均血清胆固醇从364 mg/dl降至223 mg/dl(P < 0.001),平均血清肌酐从0.77 mg/dl升至1.2 mg/dl(P < 0.01)。按组织学诊断分析,除狼疮组外,其他组蛋白尿均有相似的显著下降趋势。FSGS、狼疮性肾炎和HIV肾病患者使用CSA后血清肌酐升高;然而,血清肌酐升高仅在FSGS患者中具有统计学意义。在研究期末,20例患者发展为ESRD,其中11例为FSGS,5例为狼疮性肾炎,4例为HIV肾病。54例患者在研究期末缓解(48例蛋白尿<100 mg/24 h,6例蛋白尿<500 mg/24 h)。总之,在难治性NS患儿中,CSA使很大一部分患者缓解。然而,部分患者出现了血清肌酐升高所提示的毒性反应。由于这种毒性可能是药物所致或疾病的自然进展,仔细监测和密切随访至关重要。